Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

被引：31

作者：

Plesner, Torben ^{[1
]}

Arkenau, Hendrik-Tobias ^{[2
]}

Lokhorst, Henk M. ^{[3
]}

Gimsing, Peter ^{[4
]}

Krejcik, Jakub ^{[1
]}

Lemech, Charlotte ^{[5
]}

Minnema, Monique C. ^{[3
]}

Lassen, Ulrik ^{[6
]}

Laubach, Jacob P. ^{[7
]}

Ahmadi, Tahamtan ^{[8
]}

Yeh, Howard ^{[9
]}

Guckert, Mary E. ^{[8
]}

Feng, Huaibao ^{[9
]}

Brun, Nikolai Constantin ^{[10
]}

Lisby, Steen ^{[11
]}

Basse, Linda ^{[10
]}

Palumbo, Antonio ^{[12
]}

Richardson, Paul G. ^{[13
,14
]}

机构：

[1] Vejle Hosp, Velje, Denmark

[2] Sarah Cannon Res Insitute, London, England

[3] UMC Utrecht, Utrecht, Netherlands

[4] Univ Copenhagen, Copenhagen, Denmark

[5] Sarah Cannon Res Inst, London, England

[6] Rigshosp, DK-2100 Copenhagen, Denmark

[7] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Janssen, Spring House, PA USA

[9] Janssen Res & Dev, Raritan, NJ USA

[10] Genmab AS, Copenhagen, Denmark

[11] Genmab, Copenhagen, Denmark

[12] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy

[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut,Dept Med Oncol, Boston, MA 02115 USA

[14] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.84.84

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
[J]. HAEMATOLOGICA, 2014, 99 : 104 - 104
[2] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Plesner, Torben
Arkenau, Hendrik-Tobias
Lokhorst, Henk M.
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte Rose
Minnema, Monique
Lassen, Ulrik Niels
Ahmadi, Tahamtan
Yeh, Howard
Guckert, Mary
Brun, Nikolai C.
Lisby, Steen
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma
Plesner, Torben
Arkenau, Tobias
Lokhorst, Henk
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Cakana, Andrew
Brun, Nikolai Constantin
Basse, Linda
Palumbo, Antonio
Richardson, Paul G.
[J]. BLOOD, 2013, 122 (21)
[4] Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
贾亚静
[J]. China Medical Abstracts (Internal Medicine), 2020, 37 (03) : 189 - 189
[6] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, Adrian
Vicuna, Isabel
Aguado, Beatriz
[J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
[7] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel
Gary J. Schiller
Christy Samaras
Michael Sebag
Jesus Berdeja
Siddhartha Ganguly
Jeffrey Matous
Kevin Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald Quick
Bertrand Anz
Gustavo Fonseca
Donna Reece
William E. Pierceall
Weiyuan Chung
Faiza Zafar
Amit Agarwal
Nizar J. Bahlis
[J]. Leukemia, 2020, 34 : 3286 - 3297
[8] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Siegel, David S.
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Pierceall, William E.
Chung, Weiyuan
Zafar, Faiza
Agarwal, Amit
Bahlis, Nizar J.
[J]. LEUKEMIA, 2020, 34 (12) : 3286 - 3297
[9] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
Moreau, P.
White, D.
Benboubker, L.
Cook, G.
Leiba, M.
Morton, J.
Ho, P. J.
Kim, K.
Takezako, N.
Trivedi, S.
Wu, K.
Casneuf, T.
Chiu, C.
Schecter, J. M.
Dimopoulos, M. A.
[J]. HAEMATOLOGICA, 2018, 103 : 31 - 31
[10] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Trivedi, Sonali
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Schecter, Jordan
Moreau, Philippe
[J]. BLOOD, 2017, 130

← 1 2 3 4 5 →